OncLive TV

Ramez N. Eskander, MD, discusses the limitations of biomarker analyses for guiding treatment decisions in pMMR endometrial cancer.

Yelena Y. Janjigian, MD, discusses future research directions with nivolumab-based treatments in gastric, GEJ, and esophageal cancer.

Rachel Grisham, MD, discusses the FDA approval of avutometinib plus defactinib for KRAS-mutated, recurrent low-grade serous ovarian cancer.

Vivek G. Patel, MD, discusses the safety profile of bispecific antibodies for the treatment of patients with follicular lymphoma.

Lorenzo Falchi, MD, discusses the safety and efficacy of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma.

Kathryn E. Beckerman, MD, PhD, details the rationale for evaluating tivozanib/nivolumab following immune checkpoint inhibitors in renal cell carcinoma.

Kimberly Perez MD, discusses the FDA approval of belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

Tanya B. Dorff, MD, discusses the clinical characteristics and treatment preferences for initiating relugolix during prostate cancer treatment

David S. Hong, MD, discusses the FDA’s full approval of larotrectinib for patients with solid tumors harboring an NTRK gene fusion.

Alberto Chiappori, MD, discusses the inclusion of patients with CNS metastases in the eXALT3 trial of ensartinib in ALK-positive NSCLC.

Bogdana Schmidt, MD, MPH, details the emergence of novel treatment delivery methods in bladder cancer.

Paolo Tarantino, MD, discusses the expanding role of T-DXd in HER2-positive breast cancer.

Amin Sobh, PhD, discusses ongoing efforts to investigate the role of NSD2 expression in modulating immune surveillance in multiple myeloma.

Seema A. Bhat, MD, discusses the lack of highly effective treatment options for patients with double-refractory CLL.

Jorge A. Garcia, MD, discusses the clinical impact of the FDA’s expanded approval of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC.

Joseph C. Murray, MD, PhD, discusses the safety profiles of encorafenib/binimetinib and dabrafenib/trametinib in patients with BRAF V600E–mutant NSCLC.

Paolo Tarantino, MD, discusses the clinical implications of current risk stratification methods for patients with HER2-positive breast cancer.

Nusrat Jahan, MD, explains the role of T-DXd as the first cytotoxic therapy in patients with HR-positive/HER2-low or -ultralow breast cancer.

Deena M. Atieh Graham, MD, discusses the FDA approval of mirvetuximab soravtansine.

Deena M. Atieh Graham, MD, discusses ongoing studies of note in patients with ovarian cancer following World Ovarian Cancer Day.

Matthew Wagar, MD, discusses the addition of T-DXd to the HER2-positive endometrial cancer treatment paradigm.

Timothy S. Fenske, MD, MS, discusses the rationale for evaluating the role of standard auto-HCT in MCL given recent updates to the MCL treatment paradigm.

Nataliya Uboha, MD, PhD, discusses how biomarkers help guide treatment decision-making in esophageal adenocarcinoma.

Nerea Lopetegui-Lia, MD, elaborates on several highly anticipated studies evaluating ADCs that could shape the future TNBC treatment paradigm.

Amer Zeidan, MBBS, discusses completed and ongoing research evaluating immunotherapy and other novel agents in patients with myelodysplastic syndromes.

Rami Komrokji, MD, discusses several trials that supported the FDA approval of luspatercept for the treatment of patients with MDS with anemia.

Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Brad S. Kahl, MD, details the outcomes of bortezomib plus bendamustine/rituximab in patients with mantle cell lymphoma.

Erica Maria Pimenta, MD, PhD, discusses the future for evaluating tumor progression and immune evasion in soft tissue sarcomas.

Megan Kruse, MD, discusses long-term outcomes adjuvant abemaciclib with endocrine therapy in HR-positive, HER2-negative, high-risk early breast cancer.